Inflammation | European Cystic Fibrosis Society (ECFS)

Cystic Fibrosis Year in Review 2025

Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal health in children with cystic fibrosis

Pre-clinical development of a new molecule to treat chronic lung inflammation

Can we measure effectiveness of new cystic fibrosis treatments in improving lung health in children with cystic fibrosis aged less than 2 years of age during clinical trials conducted for the approval of new medicines?

Nasal lavage as a promising tool to monitor upper airway health

Investigating the diagnostic potential of small cell particles in the blood of people with CF

Effect of ETI on CF Gastrointestinal Disease

ivacaftor does not change gut bacteria, inflammation or pancreas function

How ivacaftor changes inflammation and protein levels in the bloodstream of people with CF and the G551D mutation

Neutrophils do not produce more oxidants when stimulated to fight infections in cystic fibrosis

1
2
3
4
next
last